ASLAN Pharmaceuticals : Notice of Transfer of Listing to The Nasdaq Capital Market - Form 6-K

Notice of Transfer of Listing to The Nasdaq Capital Market

On September 14, 2022, ASLAN Pharmaceuticals Limited (the "Company") submitted to the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") an application to transfer the listing of its American Depositary Shares ("ADSs") representing ordinary shares of the Company from The Nasdaq Global Market to The Nasdaq Capital Market. On September 27, 2022, the Company received notice from Nasdaq that its application to transfer listing of its ADSs had been approved. The transfer will be effective at the opening of business on September 29, 2022. The Company will continue to trade under the symbol "ASLN."

The Nasdaq Capital Market is a continuous trading market that operates in the same manner as The Nasdaq Global Market. All companies listed on The Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards. The Company believes it is in compliance with all applicable criteria for continued listing on The Nasdaq Capital Market, but for the $1.00 bid price requirement, as previously announced on Form 6-K filed by the Company on April 1, 2022. The Company is eligible for an additional 180-day period (or until March 27, 2023) to regain compliance with the minimum bid price, which requires that the closing bid price of the Company's ADSs must be at least $1.00 per share for a minimum of ten consecutive business days. In the event that the Company is not able to regain compliance during the additional 180-day compliance period, the Company intends to effect a reverse stock split or ADS ratio change, if necessary.

The information contained in this Form 6-K is hereby incorporated by reference into the Company's Registration Statement on Form F-3 (File No. 333-234405), Registration Statement on Form F-3 (File No. 333-252575), Registration Statement on Form F-3 (File No. 333-254768), Registration Statement on Form S-8 (File No. 333-252118) and Registration Statement on Form S-8 (File No. 333-263843).